Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2023-01-25 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-01-25 English
News release - English.pdf
Regulatory Filings
2023-01-06 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Theralase Technologies Inc. It details a private placement equity financing closed on November 17, 2022, including the issuance of units, related party transactions, and exemptions under Canadian securities laws. The document is a regulatory filing reporting a material change event (financing) rather than a full financial report or earnings release. It contains detailed information about the financing transaction and insider participation but does not include financial statements or earnings data. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (14,786 characters) and detailed transaction description support this classification with high confidence.
2022-12-02 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Theralase Releases Q322 Interim Financial Statements' and contains detailed unaudited condensed interim consolidated financial statements for the three and six-month periods ended September 30, 2022. It includes comprehensive financial data such as revenue, cost of sales, operating expenses, net loss, and operational highlights. The document also discusses clinical study updates and financing activities but primarily focuses on presenting interim financial results for Q3 2022. The length is substantial (15,000 characters), and the content includes actual financial statements and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-11-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form (Form 52-109F2) signed by the CFO certifying the accuracy and fairness of the interim financial report and interim MD&A for the period ended September 30, 2022. It does not contain the actual interim financial statements or substantive financial data but is an attestation regarding those filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3237 characters) and is clearly a certification form, not the full interim report.
2022-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109F2 Certification of Interim Filings, signed by the Interim CEO/CSO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. It is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, referencing National Instrument 52-109. The document does not contain actual financial statements or substantive financial data but serves as a regulatory attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself.
2022-11-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.